AU664189B2 - Modulation of cellular response to external stimuli - Google Patents

Modulation of cellular response to external stimuli Download PDF

Info

Publication number
AU664189B2
AU664189B2 AU22475/92A AU2247592A AU664189B2 AU 664189 B2 AU664189 B2 AU 664189B2 AU 22475/92 A AU22475/92 A AU 22475/92A AU 2247592 A AU2247592 A AU 2247592A AU 664189 B2 AU664189 B2 AU 664189B2
Authority
AU
Australia
Prior art keywords
cells
cell
agent
amount
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22475/92A
Other languages
English (en)
Other versions
AU2247592A (en
Inventor
James A. Bianco
Stuart L Bursten
Jack W. Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of AU2247592A publication Critical patent/AU2247592A/en
Application granted granted Critical
Publication of AU664189B2 publication Critical patent/AU664189B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU22475/92A 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli Ceased AU664189B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US732227 1985-05-08
US70499291A 1991-05-24 1991-05-24
US704992 1991-05-24
US73222791A 1991-07-16 1991-07-16
PCT/US1992/004349 WO1992021344A2 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Publications (2)

Publication Number Publication Date
AU2247592A AU2247592A (en) 1993-01-08
AU664189B2 true AU664189B2 (en) 1995-11-09

Family

ID=27107424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22475/92A Ceased AU664189B2 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Country Status (7)

Country Link
EP (2) EP0573617A1 (enExample)
JP (1) JP3566719B2 (enExample)
AU (1) AU664189B2 (enExample)
CA (1) CA2109796C (enExample)
IE (1) IE921683A1 (enExample)
IL (1) IL101982A (enExample)
WO (1) WO1992021344A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
CA2112239C (en) * 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US5580873A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds to treat proliferative vascular diseases
EP0728003A1 (en) 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
AU1990195A (en) * 1994-03-08 1995-09-25 Cell Therapeutics, Inc. Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
US5843943A (en) * 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
CA2208580A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
CA2335595A1 (en) * 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US20110059994A1 (en) * 2008-01-31 2011-03-10 Korea Institute Of Science And Technology Composition for preventing or treating brain cancers
JP2011510976A (ja) * 2008-01-31 2011-04-07 韓国科学技術研究院 イノシトール１，４，５−三リン酸受容体サブタイプ３の阻害用の組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
WO1989005145A1 (en) * 1987-12-11 1989-06-15 Hoechst-Roussel Pharmaceuticals Incorporated Method of inhibiting the activity of leukocyte derived cytokines
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
IL106861A (en) * 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
ES2093138T3 (es) * 1991-05-23 1996-12-16 Hoechst Ag El empleo de 1-(5-oxohexil)-3-metil-7-n-propil-xantina en cirugia vascular.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
WO1989005145A1 (en) * 1987-12-11 1989-06-15 Hoechst-Roussel Pharmaceuticals Incorporated Method of inhibiting the activity of leukocyte derived cytokines
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions

Also Published As

Publication number Publication date
EP0573617A4 (enExample) 1994-02-09
JP3566719B2 (ja) 2004-09-15
IL101982A0 (en) 1992-12-30
WO1992021344A3 (en) 1993-12-09
IE921683A1 (en) 1992-12-02
WO1992021344A2 (en) 1992-12-10
CA2109796A1 (en) 1992-12-10
EP1214938A2 (en) 2002-06-19
IL101982A (en) 2000-02-29
CA2109796C (en) 2004-04-27
EP1214938A3 (en) 2003-08-06
EP0573617A1 (en) 1993-12-15
JPH07500085A (ja) 1995-01-05
AU2247592A (en) 1993-01-08

Similar Documents

Publication Publication Date Title
US5856115A (en) Assay for identification therapeutic agents
AU664189B2 (en) Modulation of cellular response to external stimuli
EP1778224B1 (en) Flt3 inhibitors for immune suppression
JP2753395B2 (ja) 鏡像異性体ヒドロキシル化キサンチン化合物
JP3140021B2 (ja) Ｔｎｆ阻害剤含有医薬組成物
US5440041A (en) Acetal or ketal substituted xanthine compounds
KR20200105731A (ko) 포르볼 에스테르의 조성물
WO2005056014A1 (en) Methods for suppressing an immune response or a treating a proliferative disorder
EP1401415B1 (en) Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
CA3023974A1 (en) A specific trifluoroethyl quinoline analogue for use in the treatment of apds
EP0311616B1 (en) Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases
JP2018009011A (ja) ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
Thompson et al. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma
US5795897A (en) Oxohexyl methylxanthine compounds
CN100572530C (zh) 使用L-α-溶血磷脂酰胆碱获得单核细胞体外分化成成熟树突细胞
US20220079915A1 (en) Immunosuppressive pharmaceutical composition and application thereof
EP0692251A1 (en) Use of methotrexate for the manufacture of a medicament for the treatment of lung capillary leak
Strom et al. Regulation of alloimmunity by cyclic nucleotides
Petros et al. The Pharmacologic Effects of Recombinant, Human Colony‐Stimulating Factors and Their Modulation by Theophylline
Ft F. Cellular Biology, Differentiation
CA2105378A1 (en) Compositions and methods of treatment of a variety of disorders utilizing etianate and agonists thereof
Moore et al. Acute Graft-Versus-Host Disease
Flierl et al. Upregulation of Phagocyte-Derived Catecholamines Augments the Acute Inflammatory